Quazinone (also known as Ro 13-6438 ) is a cardiotonic and vasodilator drug which was developed and marketed in the 1980s for the treatment of heart disease. The positive inotropic response to Quazinone of the isolated guinea pig papillary muscle was accompanied by inhibition of myocardial phosphodiesterase (PDE) activity and elevation of intracellular cyclic AMP (cAMP) levels Quazinone had no effect on Na+, K+-stimulated or Ca2+-stimulated ATPase activity and did not influence the rate of calcium uptake in cardiac membrane vesicles. Quazinone caused a concentration-dependent increase in the upstroke velocity, overshoot, and duration of slow action potentials evoked in partially depolarized papillary muscles. Pretreatment of guinea pigs with reserpine did not prevent the effects of Quazinone on slow action potentials but slightly decreased its positive inotropic activity. In clinical trials, Quazinone induces dose-dependent hemodynamic changes, an increase in cardiac index combined with decreases in pulmonary capillary wedge pressure and systemic and pulmonary arterial pressures.

Emakalim (EMD 56431) is ATP-sensitive potassium channel opener. It exerts vasorelaxant and cardioprotective effects. Emakalim was being developed for the treatment of hypertension and ischaemic heart disorders.

Brosuximide is longer-lasting anticonvulsant that has been studied as an antiepileptic drug.

Brovanexine is a derivative of bromhexine used as an adjunct to antibacterials in preparations for the treatment of respiratory-tract infections. Oral administration of brovanexine hydrochloride (BR-222) caused a significant increase in the output volume of respiratory tract fluid. Brovanexine at 10 and 20 mg/kg showed a tendency to reduce the viscosity of respiratory tract fluid in anesthetized dogs. Brovanexine also showed a tendency to reduce the viscosity of sputum obtained from the SO2-exposed rabbits.

Broquinaldol is a halogenated derivative of quinoline and a member of the class of compounds known as halogenated phenazines. Broquinaldol and related compounds have demonstrated efficacy against antibiotic-tolerant bacterial biofilms and Mycobacterium tuberculosis. Against several bacterial strains, broquinaldol had a minimum inhibitory concentration of 0.78 microM. Broquinaldol was also identified as having antiproliferative activity against thyroid cancer cells in vitro.

Bromofenofos is an anthelminthic agent used in veterinary medicine to treat common liver fluke (Fasciola hepatica) infections in cattle and sheep.

Salazosulfadimidine is a sulfonamide antibiotic. This drug was studied in patients with chronic inflammatory bowel disease who had developed extraintestinal manifestations when receiving sulfasalazine. Information about the current use of this drug is not available.

Quincarbate is a quinoline derivative patented by N. V. Philips' Gloeilampenfabrieken as diuretic. At 12.5 mg/kg orally in rats Quincarbate increased urine excretion by 130%.